GNFTF News and Press, Genfit Ord From 10/05/18

In June, Galmed (NASDAQ: GLMD ) announced data from its Phase 2b trial evaluating its lead drug candidate Aramchol's ability to reduce liver fat in patients with NASH fibrosis . Though the drug failed its primary endpoint, it did demonstrate a moderate ability to reduce liver fat, improve ...

Biotechs developing treatments for nonalcoholic steatohepatitis (NASH) and other fatty liver diseases are seeing some action following the release of abstracts for November's Liver Meeting in San Francisco. More news on: NGM Biopharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals...

Quick Take Tiziana Life Sciences plc ( TLSA ) is seeking to raise $16 million in a U.S. IPO, according to an amended registration statement . The company is advancing a pipeline of therapeutic candidates for various cancers and immune diseases. TLSA is developing promising treatments ...

Genfit ( OTCPK:GNFTF ): 1H EPS of -€1.11. Revenue of €64K (flat Y/Y). Press Release More news on: Genfit, Earnings news and commentary,

Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space and also provide quick commentary on other imp...

In my most recent article , I provided a segmentation of the overall NASH market (between fibrosis and cirrhosis) and briefly discussed each of the major players in the NASH fibrosis market. Now, I'd like to discuss the NASH cirrhosis market and provide an overview of the firms operating in t...

Over the past year, interest has heated up in the biotech industry about NASH, with analysts estimating market size in 2025 anywhere between $20-35 billion. Positive Phase 2 data readouts for Madrigal (NASDAQ: MDGL ) and Galmed (NASDAQ: GLMD ) caused both stocks to more than double overnight...

Leadership is solving problems - Colin Powell Investment Thesis In 2015, the stock price of Genfit (GNFTF) stumbled on the release of the top line data of the Phase 2b GOLDEN-505 study of elafibranor therapy in NASH due to misinterpretation of the results. However, reanalysis of th...

Quick Take Tiziana Life Sciences ( TLSA ) intends to raise gross proceeds of $11.5 million from a U.S. IPO, according to an F-1 registration statement . The firm is developing therapeutics and diagnosis for cancers and immune diseases. TLSA is preparing for Phase 3 trials for its le...

Hallmark Moments... Writing the perfect greeting card is never easy. Wording needs to be precise. The length so exact. Find all those details you definitely want to include... or leave out. While still managing to strike just the proper tone. Nothing too dark and serious, but also not too ...